Articles related to RESEARCH & CLINICAL TRIALS

“The system lacks transparency, which was the main intent of the Sunshine Act.” — Krishna Nalleballe, MD, University of Arkansas for Medical Sciences

“Second-line therapy should not be dismissed outright in platinum-refractory or early-relapsing disease. It remains a relevant part of comprehensive care.” — Tingting Tan, MD, PhD, City of Hope

“Axpaxli is the first and only investigational product in wet AMD with a novel mechanism of action to successfully demonstrate superiority to an approved anti-VEGF agent since their initial approval more than 20 years ago.” — Pravin U. Dugel, MD, Ocular Therapeutix

The reseachers acknowledge that the Delphi approach favors compounds already studied and may exclude agents identifiable only through high-throughput screening.

“A 65% reduction in the risk of death and a statistically significant extension in median survival of over 14 months represent a clinically meaningful benefit of notable magnitude in ALS.” — Alon Ben-Noon, CEO, Neurosense Therapeutics

“TRD patients have extremely limited treatment options, and the unmet need remains profound.” — Guy Goodwin, MD, CMO, Compass Pathways